Considering investing in crispr stocks? While the best crispr stocks depend on your portfolio and investment goals, we've identified some crispr stocks that are worth keeping an eye on in the gene editing sector. Keep reading to learn more about crispr stocks and how to start investing.
We round up a selection of stocks in or related to the gene editing industry, weighting the list more heavily towards popular mid- and large-cap stocks.
| Best stock | 1-year return | Market cap | Exchange | Volume | Buy now on CIBC Investor's Edge |
|---|---|---|---|---|---|
| Crispr Therapeutics (CRSP.US) | 35.55% | $5.4 billion (USD) | NASDAQ | 1,175,613 | Buy now |
| Editas Medicine (EDIT.US) | 76.87% | $247 million (USD) | NASDAQ | 1,935,493 | Buy now |
| Regeneron Pharmaceuticals (REGN.US) | 5.87% | $78.6 billion (USD) | NASDAQ | 754,965 | Buy now |
| Cellectis (CLLS.US) | 149.69% | $469.5 million (USD) | NASDAQ | 78,088 | Buy now |
| Beam Therapeutics Inc (BEAM.US) | -4.66% | $2.7 billion (USD) | NASDAQ | 1,456,407 | Buy now |
| Bluebird bio (BLUE.US) | (data unavailable) | $48.7 million (USD) | NASDAQ | (data unavailable) | Buy now |
| Sangamo Therapeutics (SGMO.US) | -81.03% | $148.1 million (USD) | NASDAQ | 3,115,197 | Buy now |
The gene editing industry is affected by a range of complex factors such as trade policies, regulations, and fluctuating supply and demand. So when considering crispr stocks to buy, it's important that you have access to vital information about a company's financial health, leadership team, and market positioning.
Also keep in mind that, while volatility can be ideal for day traders, long-term investors will want to look for stocks to offer steadier gains over time.
A lot of factors go into picking the best crispr stocks. Stock performance can be impacted by factors like market conditions, company decisions and global events. Plus, what may be a strong crispr stock investment for one person might not be suitable for another.
That said, we rounded up this list of popular crispr stocks in or related to the gene editing industry to help narrow down your options:
Keep in mind that this is not a "best" list or a recommendation. It highlights some crispr stocks for informational purposes only and does not indicate past or future performance or investment advice. We do not guarantee any investment performance.
We've outlined detailed company and stock performance details for each crispr stock below. Keep reading to decide if any of these companies are the right investment for you.
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. The company's CRISPR/Cas9 is a revolutionary technology for gene editing which is the process of precisely altering specific sequences of genomic DNA. It has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, CAR T cell therapies, in vivo, and type 1 diabetes, as well as develops investigational CAR T programs, including an autologous, gene-edited CAR T program targeting glypican-3 (GPC3) for the potential treatment of solid tumors.
| Closing stock price | $54.74 |
|---|---|
| Market Capitalization | $5.4 billion |
| Gross profit (TTM) | $-430,665,984 |
| Revenue (TTM) | $38.3 million |
| Earnings per share (TTM) | -$5.54 |
| 52-week stock price range | $30.04 – $78.48 |
Editas Medicine, Inc. , a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. The company develops a proprietary gene editing platform based on CRISPR technology.
| Closing stock price | $2.37 |
|---|---|
| Market Capitalization | $247 million |
| Gross profit (TTM) | $-64,777,000 |
| Revenue (TTM) | $46.4 million |
| Earnings per share (TTM) | -$2.35 |
| 52-week stock price range | $0.91 – $4.54 |
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.
| Closing stock price | $749.79 |
|---|---|
| Market Capitalization | $78.6 billion |
| Gross profit (TTM) | $6.5 billion |
| Profit margin | 32.13% |
| Revenue (TTM) | $14.2 billion |
| Earnings per share (TTM) | $41.73 |
| 52-week stock price range | $475.17 – $790.98 |
Cellectis S. A. , a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates in the field of immuno-oncology and gene therapy product candidates in other therapeutic indications.
| Closing stock price | $3.97 |
|---|---|
| Market Capitalization | $469.5 million |
| Gross profit (TTM) | $82.6 million |
| Profit margin | -42.83% |
| Revenue (TTM) | $82.6 million |
| Earnings per share (TTM) | -$0.33 |
| 52-week stock price range | $1.10 – $5.48 |
Beam Therapeutics Inc. , a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease; BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a.
| Closing stock price | $25.60 |
|---|---|
| Market Capitalization | $2.7 billion |
| Gross profit (TTM) | $-356,086,016 |
| Revenue (TTM) | $55.7 million |
| Earnings per share (TTM) | -$4.41 |
| 52-week stock price range | $13.53 – $35.25 |
bluebird bio, Inc. , a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company's product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; LYFGENIA (lovotibeglogene autotemcel) for the treatment of sickle cell disease (SCD) and a history of vaso-occlusive events; and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.
| Market Capitalization | $48.7 million |
|---|---|
| Gross profit (TTM) | $28.2 million |
| Profit margin | -192.39% |
| Revenue (TTM) | $103.9 million |
| Earnings per share (TTM) | -$20.59 |
| 52-week stock price range | $3.20 – $10.28 |
Sangamo Therapeutics, Inc. , a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; and SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A.
| Closing stock price | $0.44 |
|---|---|
| Market Capitalization | $148.1 million |
| Gross profit (TTM) | $-72,032,000 |
| Revenue (TTM) | $32.9 million |
| Earnings per share (TTM) | -$0.44 |
| 52-week stock price range | $0.38 – $2.82 |
Compare special offers, low fees and a wide range of investment options among popular trading platforms in Canada. Note that the dollar amounts in the table below are in CAD.
To make comparing even easier we came up with the Finder Score. Trading costs, account fees and features across 10+ stock trading platforms and apps are all weighted and scaled to produce a score out of 10. The higher the score, the better the platform—it's that simple.
We break down which companies hold Ethereum, why they’re doing it and what ETH treasuries mean for markets and investors.
Want to invest in the Euro Stoxx 50 in Canada? Explore investment platforms and popular Euro Stoxx 50 index funds.
What are the best stocks for beginners with little money to invest?
Want to dive into investing but don’t have much to spend? Take a look at these types of stocks.
Want to invest in sports companies? We’ve put together a list of sports stocks you should keep your eye on.
Learn how a stop-loss order can help you limit losses or lock in profits when trading.
These are the best renewable energy stocks to buy now in Canada.
Check out some of the best gold stocks to buy right now in Canada based on company performance.
Finder’s unique algorithm found the 20 best TSX stocks to buy right now.
Your guide to inverse ETFs, their pros and cons, and how to invest in short ETFs.
Learn how to choose the best ETFs to buy right now in Canada.
Round up your spare change into big bucks with Canadian apps designed for saving, depositing and investing.
Compare four ways to invest in gold in Canada and learn the pros and cons of investing in gold.
Compare defensive and growth investments to find the best investment accounts in Canada for you.
